Form 4: Abeona Therapeutics CEO Vishwas Seshadri Reports Tax-Related Stock Transaction
SEC Form 4 Filing
Abeona Therapeutics' CEO, Vishwas Seshadri, reports a transaction involving the surrender of restricted stock to cover tax obligations upon vesting.
Summary
- On June 3, 2024, Vishwas Seshadri, CEO of Abeona Therapeutics, reported a transaction involving common stock.
- Seshadri surrendered 703 shares of restricted stock to satisfy tax withholding obligations upon the vesting of restricted stock.
- The transaction was exempt under Rule 16b-3(e).
- Following the transaction, Seshadri beneficially owns 537,557 shares of Abeona Therapeutics common stock directly.
Sentiment
Score: 5
Explanation: This is a neutral event related to tax obligations and doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for executives to surrender shares to cover taxes upon the vesting of restricted stock.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of the stock transaction (surrender of shares for tax withholding). |
| 06/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.